Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX) announced inducement equity awards granted on February 1, 2026 under its 2023 Inducement Plan. The company granted options to purchase up to 11,600 shares to two new employees.

The options vest over four years: 25% after one year and the remainder monthly (1/48th) over the following 36 months, subject to continued service.

Market Reaction

+4.06% $21.26

15m delay 1 alert

+4.06% Since News

$21.26 Last Price

$20.43 $21.26 Day Range

+$72M Valuation Impact

$1.85B Market Cap

0.1x Rel. Volume

Following this news, SNDX has gained 4.06%, reflecting a moderate positive market reaction. The stock is currently trading at $21.26. This price movement has added approximately $72M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Inducement options granted: 11,600 shares Grant date: February 1, 2026 Vesting period: 4 years +5 more

8 metrics

Inducement options granted 11,600 shares Stock options to two new employees under 2023 Inducement Plan

Grant date February 1, 2026 Date options were granted as inducement awards

Vesting period 4 years Total vesting duration for the stock options

Initial vesting tranche 25% Vests on one-year anniversary of vesting commencement date

Subsequent vesting schedule 1/48th monthly Monthly vesting over remaining 36 months after first anniversary

Remaining vesting duration 36 months Monthly vesting period following initial 25% cliff

Number of employees 2 employees Recipients of the inducement stock option awards

Plan name 2023 Inducement Plan Equity plan under which these options were granted

Market Reality Check

Price: $20.43 Vol: Volume 836,130 vs 20-day ...

low vol

$20.43 Last Close

Volume Volume 836,130 vs 20-day average 1,300,136 (relative volume 0.64). low

Technical Price $21.25 is trading above 200-day MA at $14.79, near 52-week high $22.73.

Peers on Argus

SNDX slipped 0.47% with mixed peer moves: ARDX -1.4%, BHVN -2.57%, VRDN -3.54%, ...

SNDX slipped 0.47% with mixed peer moves: ARDX -1.4%, BHVN -2.57%, VRDN -3.54%, while VERA rose 0.61% and TRML was flat, suggesting stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim 2025 results	Positive	-1.3%	Preliminary 4Q25 and 2025 revenue, cash and 2026 expense outlook disclosed.
Jan 07	Access program deal	Positive	+8.7%	Managed Access Program with WODA to expand Revuforj access internationally.
Jan 05	Conference presentation	Neutral	-5.1%	Announcement of CEO presentation slot at J.P. Morgan Healthcare Conference.
Dec 12	Drug award news	Positive	-0.2%	Revuforj named Best New Drug at Scrip Awards 2025 after recent approvals.
Dec 08	Clinical data update	Positive	-1.7%	Multiple strong Revuforj datasets presented at ASH 2025 across leukemia settings.

Pattern Detected

Recent history shows SNDX often trading weaker after positive or neutral news, with four of the last five announcements followed by negative 24-hour moves despite generally constructive business and clinical updates.

Recent Company History

Over the last few months, Syndax has reported growing product revenues, global access expansion for Revuforj, and visibility through major conferences and awards. Notable items include preliminary 2025 revenues for Revuforj and Niktimvo on Jan 12, 2026, a multi-regional access program announcement on Jan 7, 2026, and recognition of Revuforj as Best New Drug in Dec 2025. Strong ASH 2025 clinical data were also highlighted. Against this backdrop, the current inducement grant is a routine corporate event rather than a major strategic shift.

Market Pulse Summary

This announcement details a small inducement grant of 11,600 stock options under the 2023 Inducement...

Analysis

This announcement details a small inducement grant of 11,600 stock options under the 2023 Inducement Plan, vesting over 4 years per NASDAQ Listing Rule 5635(c)(4). In context, SNDX shares traded above the $14.79 200-day MA and within 6.51% of the 52-week high, following recent updates on revenues, access programs, and clinical data. Investors may monitor future hiring- and compensation-related disclosures alongside upcoming financial and clinical milestones.

Key Terms

NASDAQ Listing Rule 5635(c)(4)

1 terms

NASDAQ Listing Rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the Company granted inducement awards to purchase up to 11,600 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What inducement grants did Syndax (SNDX) announce on February 1, 2026?

Syndax granted inducement stock options to two new employees to purchase up to 11,600 shares. According to the company, the awards were made under the 2023 Inducement Plan and are intended as hiring incentives for new hires.

How do the Syndax (SNDX) inducement stock options vest and over what timeline?

The options vest over four years with 25% vesting after one year, then monthly thereafter. According to the company, the remaining shares vest at 1/48th per month over the subsequent 36 months, subject to continued service.

How many employees received inducement awards from Syndax (SNDX) on February 1, 2026?

Two new employees received inducement awards to purchase up to 11,600 shares in total. According to the company, the grants were issued under the 2023 Inducement Plan as hiring-related equity awards.

Do the Syndax (SNDX) inducement awards dilute existing shareholders immediately?

The awards potentially increase outstanding shares if options are exercised, but do not dilute immediately upon grant. According to the company, dilution would occur only when and if the stock options are exercised by the employees.

Under which plan were the Syndax (SNDX) inducement awards issued and why does it matter?

The awards were issued under the company's 2023 Inducement Plan, which governs new-hire equity grants. According to the company, using the inducement plan allows issuance outside existing equity plans to incentivize new employees.